EP2899198A4 - Synthetisches pntx (19)-peptide, pharmazeutische zusammensetzungen und verwendung - Google Patents

Synthetisches pntx (19)-peptide, pharmazeutische zusammensetzungen und verwendung

Info

Publication number
EP2899198A4
EP2899198A4 EP13831141.0A EP13831141A EP2899198A4 EP 2899198 A4 EP2899198 A4 EP 2899198A4 EP 13831141 A EP13831141 A EP 13831141A EP 2899198 A4 EP2899198 A4 EP 2899198A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical compositions
synthetic peptide
peptide pntx
pntx
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13831141.0A
Other languages
English (en)
French (fr)
Other versions
EP2899198B1 (de
EP2899198A1 (de
Inventor
Lima Perez Garcia Maria Elena De
Da Silva Carolina Nunes
Marco Almeida Flávia De
Silva Lomeo Rosangela Da
Beirão Paulo Sérgio Lacerda
Torres Fernanda Silva
De Castro Pimenta Adriano Monteiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade Federal de Minas Gerais
Original Assignee
Universidade Federal de Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102012020800A external-priority patent/BR102012020800A2/pt
Priority claimed from BR102013020574-5A external-priority patent/BR102013020574B1/pt
Application filed by Universidade Federal de Minas Gerais filed Critical Universidade Federal de Minas Gerais
Publication of EP2899198A1 publication Critical patent/EP2899198A1/de
Publication of EP2899198A4 publication Critical patent/EP2899198A4/de
Application granted granted Critical
Publication of EP2899198B1 publication Critical patent/EP2899198B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Insects & Arthropods (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP13831141.0A 2012-08-20 2013-08-20 Synthetisches pntx (19)-peptide, pharmazeutische zusammensetzungen und verwendung Active EP2899198B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BR102012020800A BR102012020800A2 (pt) 2012-08-20 2012-08-20 Peptídeo sintético pntx (19), composições farmacêuticas e uso
BR102013020574-5A BR102013020574B1 (pt) 2013-08-13 2013-08-13 PEPTÍDEO SINTÉTICO PnTx(19), COMPOSIÇÕES FARMACÊUTICAS E USO
PCT/BR2013/000319 WO2014028997A1 (pt) 2012-08-20 2013-08-20 Peptídeo sintético pntx(19), composições farmacêuticas e uso

Publications (3)

Publication Number Publication Date
EP2899198A1 EP2899198A1 (de) 2015-07-29
EP2899198A4 true EP2899198A4 (de) 2016-01-20
EP2899198B1 EP2899198B1 (de) 2018-05-02

Family

ID=50149301

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13831141.0A Active EP2899198B1 (de) 2012-08-20 2013-08-20 Synthetisches pntx (19)-peptide, pharmazeutische zusammensetzungen und verwendung

Country Status (8)

Country Link
US (1) US9279004B2 (de)
EP (1) EP2899198B1 (de)
JP (1) JP6430938B2 (de)
KR (1) KR102103715B1 (de)
CL (1) CL2015000415A1 (de)
MX (1) MX362058B (de)
PT (1) PT2899198T (de)
WO (1) WO2014028997A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101613302B1 (ko) * 2015-12-30 2016-04-18 (주)넥스젠바이오텍 Sv82 폴리펩타이드 및 이를 유효성분으로 함유하는 피부 주름 개선 및 탄력 유지용 화장료 조성물
KR101636851B1 (ko) * 2016-06-03 2016-07-06 (주)넥스젠바이오텍 피부 세포 증식 효과가 증가한 열 안정성 인간 상피세포성장인자-거미독 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선 및 탄력 유지용 화장료 조성물
US10905738B2 (en) * 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
CN114302734A (zh) * 2019-09-03 2022-04-08 生物医药产品开发公司 PnPP-19用于预防和治疗眼病的方法和用途
JP2026507422A (ja) * 2023-02-17 2026-03-04 バイオゼウス バイオファーマシューティカル エス．エー． 性機能障害の治療のための局所用ペプチド製剤
WO2025133214A1 (en) 2023-12-21 2025-06-26 Novaliq Gmbh Ophthalmic polypeptide compositions for the treatment of posterior eye disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007003884A1 (es) 2007-12-31 2009-09-25 Laboratorios Andromaco S A Péptido derivado del veneno de la araña viuda negra, procedimiento para preparar dicho péptido, composición farmacéutica que lo comprende, y uso de dicha composición para la preparación de un medicamente útil para el tratamiento de la disfunción sexual.
BRPI0800596A2 (pt) * 2008-01-31 2009-09-22 Univ Minas Gerais método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014028997A1 *
TORRES F S ET AL: "Functional expression of a recombinant toxin - rPnTx2-6 - active in erectile function in rat", TOXICON, ELMSFORD, NY, US, vol. 56, no. 7, 15 December 2010 (2010-12-15), pages 1172 - 1180, XP002616327, ISSN: 0041-0101, [retrieved on 20100424], DOI: 10.1016/J.TOXICON.2010.04.010 *

Also Published As

Publication number Publication date
EP2899198B1 (de) 2018-05-02
PT2899198T (pt) 2018-06-29
KR20150084766A (ko) 2015-07-22
EP2899198A1 (de) 2015-07-29
MX362058B (es) 2019-01-07
WO2014028997A1 (pt) 2014-02-27
MX2015002279A (es) 2015-10-15
US20150218233A1 (en) 2015-08-06
CL2015000415A1 (es) 2015-09-11
US9279004B2 (en) 2016-03-08
JP6430938B2 (ja) 2018-11-28
KR102103715B1 (ko) 2020-04-23
JP2015535808A (ja) 2015-12-17

Similar Documents

Publication Publication Date Title
FR2998570B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques propigmentantes
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
EP2922877A4 (de) Verbesserte peptidarzneimittel
IL230662A0 (en) Indazoles
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
BR112015003125A2 (pt) ingrediente hidrante cosmético ou7 farmacêutico
RU2016118771A3 (en) Co-crystals and pharmaceutical compositions comprising the same
IT1398930B1 (it) Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
BR112014000049A2 (pt) pirrolotriazinas substituídas com hidroximelilarilo e sua utilização
PL2842945T3 (pl) Pochodna sulfonamidowa i jej zastosowanie medyczne
EP2833879A4 (de) Kynurenin-3-monooxygenase-hemmer, pharmazeutische zusammensetzungen und verfahren zur verwendung davon
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
EP2870958A4 (de) Feuchthaltemittel und kosmetikum damit
CL2014003283A1 (es) Formulación farmacéutica.
IL246246A0 (en) Converted piperidinyl-tetrahydroquinolines and their use as alpha-c2-adrenoreceptor antagonists
EP2855506A4 (de) Peptid und verwendung davon
EP2808349A4 (de) Triblockcopolymer und verwendung davon
EP2837627A4 (de) Amidopyridinderivat und verwendung davon
EP2899198A4 (de) Synthetisches pntx (19)-peptide, pharmazeutische zusammensetzungen und verwendung
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
EP2687532A4 (de) Neues octahydrothienochinolinderivat, pharmazeutische zusammensetzung mit diesem derivat und verwendung davon
BR112014032501A2 (pt) composto, e, composição farmacêutica.
EP3302483A4 (de) Pharmazeutische zusammensetzungen und verwendung davon
FR2991169B1 (fr) Composition cosmetique ou dermatologique et son utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150320

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151221

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/10 20060101ALI20151215BHEP

Ipc: C07K 7/08 20060101AFI20151215BHEP

Ipc: C07K 14/435 20060101ALI20151215BHEP

Ipc: A61P 15/10 20060101ALI20151215BHEP

Ipc: A61K 38/00 20060101ALI20151215BHEP

17Q First examination report despatched

Effective date: 20170202

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20171113

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 995134

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180515

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013037018

Country of ref document: DE

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER AND PEDRAZZINI AG, CH

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2899198

Country of ref document: PT

Date of ref document: 20180629

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20180622

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2677149

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180730

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180802

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E039194

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013037018

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

26N No opposition filed

Effective date: 20190205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180820

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 995134

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180502

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180502

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180502

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180902

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20250812

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250909

Year of fee payment: 13

Ref country code: PT

Payment date: 20250805

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250828

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20250806

Year of fee payment: 13

Ref country code: NL

Payment date: 20250828

Year of fee payment: 13

Ref country code: IT

Payment date: 20250828

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20250826

Year of fee payment: 13

Ref country code: GB

Payment date: 20250805

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250828

Year of fee payment: 13

Ref country code: AT

Payment date: 20250826

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250901

Year of fee payment: 13